Other analysts also recently issued reports about the company. HC Wainwright lowered their price target on Galectin Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, May 17th. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 1st.
GALT stock opened at $1.44 on Friday. The company has a market cap of $85.52 million, a price-to-earnings ratio of -2.48 and a beta of 1.66. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 79.37. The business has a fifty day simple moving average of $1.49 and a 200-day simple moving average of $1.87. Galectin Therapeutics has a 52 week low of $1.19 and a 52 week high of $4.40.
A number of large investors have recently bought and sold shares of GALT. Atria Wealth Solutions Inc. purchased a new position in Galectin Therapeutics in the 1st quarter valued at about $460,000. Renaissance Technologies LLC boosted its holdings in Galectin Therapeutics by 2,033.5% in the fourth quarter. Renaissance Technologies LLC now owns 215,400 shares of the company’s stock worth $446,000 after purchasing an additional 205,304 shares during the period. Geode Capital Management LLC increased its stake in Galectin Therapeutics by 32.2% during the third quarter. Geode Capital Management LLC now owns 540,866 shares of the company’s stock valued at $2,098,000 after purchasing an additional 131,853 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Galectin Therapeutics by 15.8% during the fourth quarter. Millennium Management LLC now owns 405,601 shares of the company’s stock worth $840,000 after purchasing an additional 55,265 shares during the period. Finally, Synovus Financial Corp bought a new position in shares of Galectin Therapeutics in the 4th quarter worth about $99,000. 12.35% of the stock is owned by institutional investors.
About Galectin Therapeutics (Get Rating)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- The Institutions Are Rotating Into Olli’s Bargain Outlet
- Inflation, An Economic Winter Is Approaching
- Microcap Oil-Dri Corporation Is A Buy For Income Investors
- Would Netflix acquiring Roku be a positive for the stock?
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.